Akira Kanamoto

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
  2. ncbi Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
    Toshiyuki Baba
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokane dai, Minato city, Tokyo, 108 8639, Japan
    J Transl Med 8:84. 2010

Detail Information

Publications2

  1. ncbi Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  2. ncbi Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
    Toshiyuki Baba
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokane dai, Minato city, Tokyo, 108 8639, Japan
    J Transl Med 8:84. 2010
    ..Since it is the most common HLA Class I allele in the Japanese population, we performed a phase I clinical trial of cancer vaccination using the HLA-A*2402 gp100 peptide to treat patients with metastatic melanoma...